Chen Kan, Cao Wanlu, Li Juan, Sprengers Dave, Hernanda Pratika Y, Kong Xiangdong, van der Laan Luc J W, Man Kwan, Kwekkeboom Jaap, Metselaar Herold J, Peppelenbosch Maikel P, Pan Qiuwei
Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Bio-X Center, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, China.
Mol Med. 2016 Jan;21(1):792-802. doi: 10.2119/molmed.2015.00126. Epub 2015 Oct 13.
As uncontrolled cell proliferation requires nucleotide biosynthesis, inhibiting enzymes that mediate nucleotide biosynthesis constitutes a rational approach to the management of oncological diseases. In practice, however, results of this strategy are mixed and thus elucidation of the mechanisms by which cancer cells evade the effect of nucleotide biosynthesis restriction is urgently needed. Here we explored the notion that intrinsic differences in cancer cell cycle velocity are important in the resistance toward inhibition of inosine monophosphate dehydrogenase (IMPDH) by mycophenolic acid (MPA). In short-term experiments, MPA treatment of fast-growing cancer cells effectively elicited G0/G1 arrest and provoked apoptosis, thus inhibiting cell proliferation and colony formation. Forced expression of a mutated IMPDH2, lacking a binding site for MPA but retaining enzymatic activity, resulted in complete resistance of cancer cells to MPA. In nude mice subcutaneously engrafted with HeLa cells, MPA moderately delayed tumor formation by inhibiting cell proliferation and inducing apoptosis. Importantly, we developed a lentiviral vector-based Tet-on label-retaining system that enables to identify, isolate and functionally characterize slow-cycling or so-called label-retaining cells (LRCs) and . We surprisingly found the presence of LRCs in fast-growing tumors. LRCs were superior in colony formation, tumor initiation and resistance to MPA as compared with fast-cycling cells. Thus, the slow-cycling compartment of cancer seems predominantly responsible for resistance to MPA.
由于不受控制的细胞增殖需要核苷酸生物合成,抑制介导核苷酸生物合成的酶构成了一种治疗肿瘤疾病的合理方法。然而,在实际应用中,该策略的结果喜忧参半,因此迫切需要阐明癌细胞逃避核苷酸生物合成限制作用的机制。在此,我们探讨了癌细胞周期速度的内在差异在对霉酚酸(MPA)抑制肌苷单磷酸脱氢酶(IMPDH)的抗性中起重要作用这一观点。在短期实验中,用MPA处理快速生长的癌细胞可有效诱导G0/G1期阻滞并引发凋亡,从而抑制细胞增殖和集落形成。强制表达一种突变的IMPDH2,该突变体缺乏与MPA的结合位点但保留酶活性,导致癌细胞对MPA完全耐药。在皮下接种了HeLa细胞的裸鼠中,MPA通过抑制细胞增殖和诱导凋亡适度延迟了肿瘤形成。重要的是,我们开发了一种基于慢病毒载体的Tet-on标记保留系统,该系统能够识别、分离和功能表征慢循环或所谓的标记保留细胞(LRCs)。我们惊讶地发现在快速生长的肿瘤中存在LRCs。与快速循环细胞相比,LRCs在集落形成、肿瘤起始和对MPA的抗性方面更具优势。因此,癌症的慢循环部分似乎主要负责对MPA的抗性。